{"id":"alprostadil-liposomes-for-injection","safety":{"commonSideEffects":[{"rate":"null","effect":"Flushing"},{"rate":"null","effect":"Hypotension"},{"rate":"null","effect":"Pain at injection site"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Alprostadil is a synthetic form of prostaglandin E1, which stimulates the vasodilation of blood vessels.","oneSentence":"vasodilation via prostaglandin E1 receptor agonism","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:44.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary hypertension"},{"name":"Cerebral vasospasm"}]},"trialDetails":[{"nctId":"NCT05475717","phase":"PHASE2","title":"A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI","status":"TERMINATED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2022-10-20","conditions":"Contrast-induced Acute Kidney Injury","enrollment":132},{"nctId":"NCT04197323","phase":"PHASE2","title":"Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-10-01","conditions":"Peripheral Artery Disease","enrollment":20},{"nctId":"NCT03669562","phase":"PHASE1","title":"The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2018-08-07","conditions":"Lower Extremity Arterial Occlusive Diseases","enrollment":48},{"nctId":"NCT02877173","phase":"PHASE2","title":"A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans","status":"UNKNOWN","sponsor":"Guangzhou Yipinhong Pharmaceutical CO.,LTD","startDate":"2016-08","conditions":"Arteriosclerosis Obliterans","enrollment":160},{"nctId":"NCT02889822","phase":"PHASE1","title":"The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Guangzhou Yipinhong Pharmaceutical CO.,LTD","startDate":"2010-03","conditions":"Cardiovascular Diseases","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["No other names"],"phase":"phase_2","status":"active","brandName":"Alprostadil Liposomes for Injection","genericName":"Alprostadil Liposomes for Injection","companyName":"Guangzhou Yipinhong Pharmaceutical CO.,LTD","companyId":"guangzhou-yipinhong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"vasodilation via prostaglandin E1 receptor agonism Used for Pulmonary hypertension, Cerebral vasospasm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}